|
|
|
| home > ebr > winter 2019 > challenges for small businesses in the global pharma market |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
|
The pharmaceutical industry was considered a relatively ‘safe’ environment in which to be employed in the early 1990s. It was seen by many to be a recession-proof business where intellectual property (IP) and patents in particular were critical to profitability.
The business was global and powered by huge researchbased companies: Big Pharma, who took drugs all the way from preclinical research, through clinical development, to commercialisation. Companies like Glaxo, Merck, Pfizer, Eli Lilly, Bayer, and, in Sweden, the likes of Astra and Pharmacia, were multinational R&D-based powerhouses that dominated the life sciences landscape. In 1995, Astra had the biggest selling drug in the world: the proton pump inhibitor Losec® (omeprazole) and employed thousands of people in R&D. To its employees (which included the author at the time), the company seemed invincible.
The Changing Landscape
Drugs commanded high prices in the developed world, which represented almost the entire market in terms of value, with the US market being by far the most lucrative. Although the Hatch- Waxman Act – a US federal law designed to encourage generic drug manufacture and sale with a view to lowering prices – had been around for just a few years, generics companies were still somewhat smaller and often local organisations that tended not to enter the market until at least the basic patent covering a drug expired.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme
Luina Bio, a leading biopharmaceutical manufacturing company in
Australia, today announced it will develop and produce an innovative
bacterial drug product for Genome & Company to support its clinical
trials programme. The relationship signals Luina Bio’s first foray into
Asia and further establishes its global leadership in the current Good
Manufacturing Practise for microbiome projects.
More info >> |
|
 |
White Papers |
 |
|
Digital Transformation of the Cold Chain
Sensitech EMEA
The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >> |
|
 |
Industry Events |
 |
INTERPHEX 2019
2-4 April 2019, Javits Center, New York
At INTERPHEX, find all of the State-of-the-Art Solutions you need to
Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier
pharmaceutical, biotechnology, and medical device development and manufacturing
event and sponsored by Parenteral Drug Association (PDA). Dedicated to
Innovation, Technologies and Knowledge, the show focuses on the entire product
development life cycle.
More info >> |
|
|
